MedPath

Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Not Applicable
Completed
Conditions
Infectious Keratitis
Interventions
Other: Ultraviolet-A and riboflavin
Registration Number
NCT01739673
Lead Sponsor
Cxlusa
Brief Summary

This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria
  1. Subjects must be 18 years of age or older.
  2. Ability to provide written informed consent.
  3. Likely to complete all study visits.
  4. Subjects must have one eye that with a diagnosis of infectious keratitis.
Read More
Exclusion Criteria
  1. A corneal perforation.
  2. Descemetocele.
  3. Pregnancy or breastfeeding.
  4. Active Herpes corneal disease.
  5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Ultraviolet-A and riboflavinUltraviolet-A and riboflavin-
Primary Outcome Measures
NameTimeMethod
Resolution of Signs and Symptoms of Infectious KeratitisSubjects will be followed until resolution of signs and symptoms, an expected average of 8 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Schwartz Laser Eye Center

🇺🇸

Scottsdale, Arizona, United States

Corneal Consultants of Colorado, PC

🇺🇸

Littleton, Colorado, United States

Minnesota Eye Consultants

🇺🇸

Minneapolis, Minnesota, United States

Davidorf Eye Group

🇺🇸

West Hills, California, United States

Center for Excellence in Eye Care

🇺🇸

Miami, Florida, United States

Ophthalmology Associates

🇺🇸

Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath